Teva Pharmaceutical Industries Ltd (TEVA) Given Average Recommendation of “Hold” by Analysts

Share on StockTwits

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have received a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $21.04.

Several research firms have recently weighed in on TEVA. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Monday, December 3rd. Bank of America reiterated a “buy” rating and set a $24.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. HSBC set a $12.00 price objective on Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Tuesday, February 5th. Credit Suisse Group reiterated a “hold” rating and set a $26.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. Finally, Piper Jaffray Companies upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $16.00 in a report on Wednesday, January 23rd.

NYSE:TEVA opened at $16.47 on Friday. Teva Pharmaceutical Industries has a fifty-two week low of $14.59 and a fifty-two week high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 1.69. The stock has a market cap of $16.75 billion, a PE ratio of 5.88, a price-to-earnings-growth ratio of 2.96 and a beta of 1.34.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, February 13th. The company reported $0.53 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Teva Pharmaceutical Industries had a positive return on equity of 18.57% and a negative net margin of 11.40%. The business had revenue of $4.56 billion for the quarter, compared to analysts’ expectations of $4.52 billion. During the same quarter in the previous year, the business posted $0.93 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was down 15.5% on a year-over-year basis. As a group, equities analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current fiscal year.

In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 1,643 shares of the business’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total transaction of $25,795.10. Following the transaction, the vice president now owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $69,326.16. Following the transaction, the insider now directly owns 2,941 shares in the company, valued at approximately $49,644.08. The disclosure for this sale can be found here. Insiders sold a total of 16,173 shares of company stock worth $273,316 in the last 90 days. Company insiders own 0.43% of the company’s stock.

Large investors have recently bought and sold shares of the business. Bruderman Asset Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 2,175.0% during the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock worth $36,000 after acquiring an additional 2,262 shares during the last quarter. Rational Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $49,000. Capital Investment Advisory Services LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $56,000. Quadrant Capital Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after acquiring an additional 4,476 shares during the last quarter. Finally, Whittier Trust Co. increased its holdings in shares of Teva Pharmaceutical Industries by 35.4% during the 4th quarter. Whittier Trust Co. now owns 5,481 shares of the company’s stock worth $84,000 after acquiring an additional 1,434 shares during the last quarter. 66.42% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What is Liquidity?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CooTek   Rating Increased to Hold at Zacks Investment Research
CooTek Rating Increased to Hold at Zacks Investment Research
Barrington Research Analysts Give Atento  a $10.00 Price Target
Barrington Research Analysts Give Atento a $10.00 Price Target
Short Interest in IsoRay, Inc.  Drops By 6.8%
Short Interest in IsoRay, Inc. Drops By 6.8%
Mitie Group PLC  Receives Consensus Recommendation of “Buy” from Brokerages
Mitie Group PLC Receives Consensus Recommendation of “Buy” from Brokerages
Critical Comparison: Weatherford International  versus Its Peers
Critical Comparison: Weatherford International versus Its Peers
Sanford C. Bernstein Analysts Give Beiersdorf  a €91.00 Price Target
Sanford C. Bernstein Analysts Give Beiersdorf a €91.00 Price Target


© 2006-2019 Ticker Report